Wilkinson Ewan A J
Department of Public Health, Liverpool, UK.
Cochrane Database Syst Rev. 2012 Aug 15(8):CD001273. doi: 10.1002/14651858.CD001273.pub2.
Leg ulcers affect up to one percent of people at some time in their life. Leg ulceration is chronic in nature with ulcers being present for months and in some cases years without healing, and with a high risk of recurrence. Management approaches include dressings and the treatment of underlying medical problems such as malnutrition, lack of minerals and vitamins, poor blood supply or infection.
To assess the effectiveness of oral zinc in healing arterial or venous leg ulcers.
For this sixth update we searched The Cochrane Wounds Group Specialised Register (searched 17 May 2012); The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 5); Ovid MEDLINE (2010 to May Week 2 2012); Ovid MEDLINE (In-Process & Other Non-Indexed Citations May 16, 2012); Ovid EMBASE (2010 to 2012 Week 19); and EBSCO CINAHL (2010 to May 2 2012). In the original version of the review a company manufacturing zinc sulphate tablets was asked for references to relevant trials.
Randomised controlled trials comparing oral zinc sulphate with placebo or no treatment in people with arterial or venous leg ulcers were eligible for inclusion. There were no restrictions on date or language of publication. The main outcome measure used was complete healing of the ulcers. Trials were eligible for inclusion if they measured ulcer healing objectively by documenting time to complete healing, proportion of ulcers healed during the study, or healing rates of ulcers.
All data extraction and assessment of trial quality were done by both authors independently.
Six small trials (183 participants) were eligible for inclusion. Four trials considered people with venous ulcers, one trial arterial ulcers and one people with mixed ulcers. In four trials, serum zinc was measured at baseline or during the trial. Pooling the four trials that compared oral zinc sulphate with placebo in people with venous ulcers showed no statistically significant difference between the two group (RR 1.22, 95%CI 0.88 to 1.68). Overall, there was no evidence of a beneficial effect of treatment with zinc sulphate on the number of ulcers healed.
AUTHORS' CONCLUSIONS: Oral zinc sulphate does not appear to aid healing of arterial and venous leg ulcers, however all included studies were small and of mediocre quality.
腿部溃疡在人们一生中的某些时候影响着高达1%的人群。腿部溃疡本质上是慢性的,溃疡会持续数月,在某些情况下会持续数年不愈合,且复发风险很高。治疗方法包括敷料以及对潜在内科问题的治疗,如营养不良、缺乏矿物质和维生素、血液供应不良或感染。
评估口服锌对治疗动脉性或静脉性腿部溃疡的有效性。
在本次第六次更新中,我们检索了Cochrane伤口小组专业注册库(检索日期为2012年5月17日);Cochrane对照试验中央注册库(CENTRAL)(《Cochrane图书馆》2012年第5期);Ovid MEDLINE(2010年至2012年5月第2周);Ovid MEDLINE(在研及其他未索引引用文献,2012年5月16日);Ovid EMBASE(2010年至2012年第19周);以及EBSCO CINAHL(2010年至2012年5月2日)。在该综述的原始版本中,向一家生产硫酸锌片的公司索要了相关试验的参考文献。
比较口服硫酸锌与安慰剂或不治疗对动脉性或静脉性腿部溃疡患者疗效的随机对照试验符合纳入标准。对发表日期或语言没有限制。主要结局指标为溃疡完全愈合。如果试验通过记录完全愈合时间、研究期间愈合的溃疡比例或溃疡愈合率来客观测量溃疡愈合情况,则该试验符合纳入标准。
所有数据提取和试验质量评估均由两位作者独立完成。
六项小型试验(183名参与者)符合纳入标准。四项试验纳入的是静脉性溃疡患者,一项试验纳入的是动脉性溃疡患者,一项试验纳入的是混合性溃疡患者。四项试验在基线或试验期间测量了血清锌。汇总四项比较口服硫酸锌与安慰剂治疗静脉性溃疡患者的试验结果,两组之间无统计学显著差异(风险比1.22,95%置信区间0.88至1.68)。总体而言,没有证据表明硫酸锌治疗对愈合的溃疡数量有有益影响。
口服硫酸锌似乎无助于动脉性和静脉性腿部溃疡的愈合,然而所有纳入研究规模较小且质量一般。